Johnson & Johnson settled approximately 9,000 Risperdal gynecomastia lawsuits in September 2021 for $800 million, averaging roughly $95,000 per claimant according to attorneys involved in the litigation. This mass settlement resolved the majority of claims from men and boys who developed abnormal breast tissue growth after taking the antipsychotic medication, often prescribed off-label to children for conditions like autism and behavioral disorders. Individual verdicts before the settlement ranged dramatically””from $500,000 to an initial $8 billion award that was later reduced to $6.8 million””reflecting the severity of harm and the strength of evidence in each case.
The Risperdal litigation represents one of the most significant pharmaceutical mass torts in recent history, spanning over a decade and exposing how Johnson & Johnson’s subsidiary Janssen Pharmaceuticals allegedly concealed and downplayed the drug’s link to gynecomastia in young males. Austin Pledger, for example, developed 46DD breasts after taking Risperdal for five years as a child to manage autism-related behavioral issues, ultimately receiving a $2.5 million verdict in February 2015. His case became emblematic of thousands of similar claims. This article examines the full scope of Risperdal gynecomastia settlements, including major verdicts, the government’s criminal prosecution of Johnson & Johnson, the current status of litigation, and what claimants should understand about the legal landscape in 2025 and beyond.
Table of Contents
- What Were the Largest Risperdal Gynecomastia Lawsuit Settlements and Verdicts?
- How Johnson & Johnson Faced Criminal Charges for Risperdal Marketing
- Why Gynecomastia Claims Developed Into Mass Litigation
- What Claimants Actually Received in Risperdal Settlements
- Are Risperdal Gynecomastia Lawsuits Still Being Filed?
- The Role of Scientific Evidence in Risperdal Litigation
- What the Risperdal Litigation Means for Future Pharmaceutical Cases
- Conclusion
What Were the Largest Risperdal Gynecomastia Lawsuit Settlements and Verdicts?
The Risperdal litigation produced some of the largest individual pharmaceutical verdicts in U.S. history, though many were subsequently reduced by judges. The most striking example came in 2019 when a Philadelphia jury awarded Nicholas Murray, a Maryland man, $8 billion in punitive damages””a figure that captured national headlines. The presiding judge later reduced this award to $6.8 million, which remains substantial but illustrates how post-trial motions can dramatically alter outcomes. The largest verdict that stood closer to its original amount was the $70 million awarded to Andrew Yount, a Tennessee teenager, in July 2016.
This represented the peak of the Philadelphia Risperdal litigation, where thousands of cases were consolidated. Other significant verdicts include a $5.9 million Montana settlement, Timothy Strange’s $500,000 award in December 2015 after being prescribed Risperdal as an adolescent for Tourette syndrome, and Shaquil Byrd’s $1 million verdict in October 2017. Byrd, who was prescribed the drug at age 9 in Troy, New York, required surgical breast removal in 2014. These individual verdicts matter because they established the legal framework and evidentiary precedent that ultimately pressured johnson & Johnson toward the $800 million mass settlement. However, claimants who opted for trial faced significant risk””some cases were dismissed, others resulted in defense verdicts, and even large awards could be reduced or tied up in appeals for years.
How Johnson & Johnson Faced Criminal Charges for Risperdal Marketing
Beyond civil lawsuits from individual plaintiffs, Johnson & Johnson and its subsidiary Janssen Pharmaceuticals faced federal criminal prosecution for their marketing practices. In November 2013, the company reached a $2.2 billion settlement with the U.S. Department of Justice for misbranding and illegal off-label promotion of Risperdal and other drugs. This settlement included a $400 million criminal fine after Janssen pleaded guilty to criminal charges, plus $1.25 billion in civil penalties.
The government’s case centered on allegations that Janssen promoted Risperdal for uses not approved by the FDA, particularly in elderly dementia patients and children with behavioral disorders, while minimizing known risks including gynecomastia. An earlier settlement of $181 million had already addressed some off-label promotion claims, but the 2013 resolution represented a comprehensive reckoning with the company’s marketing conduct. These government settlements are separate from the civil litigation brought by individual plaintiffs who developed gynecomastia. However, the federal findings strengthened plaintiffs’ cases by establishing that Johnson & Johnson had engaged in deceptive practices. The criminal plea, in particular, provided powerful evidence that the company prioritized profits over patient safety””a narrative that resonated with juries in subsequent trials.
Why Gynecomastia Claims Developed Into Mass Litigation
Risperdal works by blocking dopamine receptors in the brain, but this mechanism also affects prolactin levels. Elevated prolactin can cause breast tissue development in males, a condition called gynecomastia. Internal company documents revealed during litigation suggested that Johnson & Johnson knew about this risk but failed to adequately warn prescribers and patients, especially regarding the heightened vulnerability of children and adolescents. The drug received FDA approval in 1993 for schizophrenia in adults, but Janssen aggressively marketed it off-label for pediatric use.
Children prescribed Risperdal for autism, ADHD, and behavioral problems were particularly susceptible to developing gynecomastia because their bodies were still developing. Shaquil Byrd’s case illustrates this pattern””prescribed the drug at age 9, he developed breast tissue requiring surgical removal as a young adult. most gynecomastia plaintiffs argued that Johnson & Johnson committed a “failure to warn” by not adequately disclosing the breast growth risk on drug labels. This legal theory became harder to pursue after the FDA updated Risperdal’s warning label to include gynecomastia as a known side effect, which is one reason the litigation largely concluded by 2024.
What Claimants Actually Received in Risperdal Settlements
The $800 million mass settlement in 2021 averaged approximately $95,000 per claimant across roughly 9,000 cases. However, individual amounts varied significantly based on factors including the severity of gynecomastia, whether surgical intervention was required, the age at which the plaintiff was prescribed Risperdal, and the strength of documentation linking the drug to the condition. Plaintiffs who went to trial before the mass settlement saw wildly different outcomes. While Andrew Yount received $70 million and Austin Pledger received $2.5 million, others saw their awards reduced on appeal or waited years for final resolution.
The mass settlement offered certainty””claimants received guaranteed compensation without the risk and delay of trial””but typically at lower amounts than the largest jury verdicts. Attorneys typically worked these cases on contingency, taking 33% to 40% of any recovery, plus expenses. This means a claimant receiving the average $95,000 settlement might take home between $57,000 and $64,000 after legal fees. Some plaintiffs with particularly strong cases chose to proceed to trial rather than accept settlement offers, gambling on larger verdicts against the risk of receiving nothing.
Are Risperdal Gynecomastia Lawsuits Still Being Filed?
The gynecomastia litigation has effectively concluded. Attorneys who previously handled these cases report they are no longer accepting new gynecomastia claims related to Risperdal as of 2024-2025. Several factors contributed to this closure: the mass settlement resolved the bulk of pending cases, the statute of limitations has expired for most potential plaintiffs, and the updated FDA warning label makes failure-to-warn claims more difficult to pursue. Potential claimants who never filed suit face significant obstacles. Statutes of limitations vary by state but typically require filing within two to four years of discovering the injury and its connection to Risperdal. Someone who developed gynecomastia in the early 2000s and only now considers legal action would likely find their claim time-barred.
However, a new wave of Risperdal litigation is emerging around breast cancer rather than gynecomastia. The first breast cancer lawsuit was filed in April 2025″”Bridgett Brown v. Johnson & Johnson in Alameda County, California (Case No. 25CV119808). Over 165 people are now represented in breast cancer claims related to Risperdal’s effect on prolactin levels. A February 2025 study published in Toxicology Reports found a 59% higher breast cancer risk for Risperdal users, providing scientific support for this new litigation theory.
The Role of Scientific Evidence in Risperdal Litigation
Scientific and medical evidence proved decisive in Risperdal cases. Plaintiffs needed to establish both general causation (that Risperdal can cause gynecomastia) and specific causation (that the drug caused their particular condition). Internal company documents showing Johnson & Johnson’s awareness of the gynecomastia risk strengthened the general causation argument, while medical records and expert testimony addressed specific causation.
The 2025 Toxicology Reports study finding elevated breast cancer risk illustrates how scientific research continues to shape Risperdal litigation. This type of epidemiological evidence provides the foundation for new claims. Without peer-reviewed studies establishing a connection between Risperdal and breast cancer, attorneys would struggle to pursue this emerging litigation.
What the Risperdal Litigation Means for Future Pharmaceutical Cases
The Risperdal gynecomastia litigation established important precedents for pharmaceutical mass torts. It demonstrated that companies can face massive liability for off-label marketing and inadequate warnings, even for FDA-approved drugs. The combination of government criminal prosecution and private civil litigation created pressure from multiple directions, ultimately forcing Johnson & Johnson to resolve claims comprehensively.
The transition from gynecomastia to breast cancer litigation shows how pharmaceutical cases evolve as new scientific evidence emerges. Plaintiffs’ attorneys who built expertise during the gynecomastia litigation are now applying that knowledge to breast cancer claims. Johnson & Johnson faces the prospect of another extended litigation cycle, this time involving potentially more serious injuries and a larger plaintiff population including women.
Conclusion
The Risperdal gynecomastia litigation resulted in significant compensation for thousands of plaintiffs, highlighted by the $800 million mass settlement in 2021 and individual verdicts reaching into the tens of millions of dollars. Johnson & Johnson also paid $2.2 billion to the federal government for illegal marketing practices, including criminal fines after Janssen pleaded guilty to misbranding charges. These outcomes reflected the strength of evidence that the company knew about gynecomastia risks and failed to adequately warn patients and prescribers.
For those affected by Risperdal-related gynecomastia, the window for legal action has largely closed. However, the emergence of breast cancer litigation in 2025 signals that Johnson & Johnson’s Risperdal legal exposure continues. Anyone who took Risperdal and subsequently developed breast cancer should consult with an attorney experienced in pharmaceutical litigation to evaluate whether they have a viable claim under this new theory of liability.